Alzheimer's disease sends the wrong signals – a perspective

References

• Saura C A, Choi S Y, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao B S, Chattarji S, Kelleher R J, 3rd, Kandel E R, Duff K, Kirkwood A, Shen J. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 2004; 42: 23–36
   PubMed Web of Science ®Google Scholar
• Marambaud P, Wen P H, Dutt A, Shioi J, Takashima A, Siman R, Robakis N K. A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell 2003; 114: 635–645
   PubMed Web of Science ®Google Scholar
• Bentahir M, Nyabi O, Verhamme J, Tolia A, Horre K, Wiltfang J, Esselmann H, De Strooper B. Presenilin clinical mutations can affect γ-secretase activity by different mechanisms. J Neurochem 2006; 96: 732–742
   PubMed Web of Science ®Google Scholar
• Kumar-Singh S, Theuns J, Van Broeck B, Pirici D, Vannekens K, Corsmit E, Cruts M, Dermaut B, Wang R, Van Broeckhoven C. Mean age-of-onset of familial Alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum Mutat 2006; 27: 686–695
   PubMed Web of Science ®Google Scholar
• Wang R, Wang B, He W, Zheng H. Wild-type presenilin 1 protects against Alzheimer disease mutation-induced amyloid pathology. J Biol Chem 2006; 281: 15330–15336
   Google Scholar
• Deng Y, Tarassishin L, Kallhoff V, Peethumnongsin E, Wu L, Li Y M, Zheng H. Deletion of presenilin 1 hydrophilic loop sequence leads to impaired γ-secretase activity and exacerbated amyloid pathology. J Neurosci 2006; 26: 3845–3854
   PubMed Web of Science ®Google Scholar
• Baki L, Shioi J, Wen P, Shao Z, Schwarzman A, Gama-Sosa M, Neve R, Robakis N K. PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations. EMBO J 2004; 23: 2586–2596
   PubMed Web of Science ®Google Scholar
• Kang D E, Yoon I S, Repetto E, Busse T, Yermian N, Ie L, Koo E H. Presenilins mediate phosphatidylinositol 3-kinase/AKT and ERK activation via select signaling receptors. Selectivity of PS2 in platelet-derived growth factor signaling. J Biol Chem 2005; 280: 31537–31547
   PubMedGoogle Scholar
• Lucas J J, Hernandez F, Gomez-Ramos P, Moran M A, Hen R, Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 2001; 20: 27–39
   PubMed Web of Science ®Google Scholar
• Hernández F, Borrell J, Guaza C, Avila J, Lucas J J. Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J Neurochem 2002; 83: 1529–1533
   PubMed Web of Science ®Google Scholar
• Engel T, Hernandez F, Avila J, Lucas J J. Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci 2006; 26: 5083–5090
   PubMed Web of Science ®Google Scholar
• Repetto E, Yoon I-S, Zheng H, Kang D E. Presenilin-1 regulates epidermal growth factor receptor turnover and signaling in the endosomal-lysosomal pathway. J Biol Chem 2007; 282: 31504–31516
   PubMed Web of Science ®Google Scholar
• Neve R L, McPhie D L. The cell cycle as a therapeutic target for Alzheimer's disease. Pharmacol Ther 2006; 111: 99–113
   PubMed Web of Science ®Google Scholar
• Gervais F G, Xu D, Robertson G S, Vaillancourt J P, Zhi Y, Huang J, LeBlanc A, Smith D, Rigby M, Shearman M S, Clarke E E, Zheng H, Van Der Ploeg L H, Ruffolo S C, Thornberry N A, Xanthoudakis S, Zamboni R J, Roy S, Nicholson D W. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic Aβ peptide formation. Cell 1999; 97: 395–406
   PubMed Web of Science ®Google Scholar
• Lu D C, Rabizadeh S, Chandra S, Shayya R F, Ellerby L M, Ye X, Salvesen G S, Koo E H, Bredesen D E. A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor. Nat Med 2000; 6: 397–404
   PubMed Web of Science ®Google Scholar
• McPhie D L, Coopersmith R, Hines-Peralta A, Chen Y, Ivins K J, Manly S P, Kozlowski M R, Neve K A, Neve R L. DNA synthesis and neuronal apoptosis caused by familial Alzheimer disease mutants of the amyloid precursor protein are mediated by the p21 activated kinase PAK3. J Neurosci 2003; 23: 6914–6927
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu W, McPhie D L, Hassinger L, Neve R L. APP-BP1 mediates APP-induced apoptosis and DNA synthesis and is increased in Alzheimer's disease brain. J Cell Biol 2003; 163: 27–33
   PubMed Web of Science ®Google Scholar
• Galvan V, Gorostiza O F, Banwait S, Ataie M, Logvinova A V, Sitaraman S, Carlson E, Sagi S A, Chevallier N, Jin K, Greenberg D A, Bredesen D E. Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Proc Natl Acad Sci USA 2006; 103: 7130–7135
   PubMed Web of Science ®Google Scholar
• Saganich M J, Schroeder B E, Galvan V, Bredesen D E, Koo E H, Heinemann S F. Deficits in synaptic transmission and learning in amyloid precursor protein (APP) transgenic mice require C-terminal cleavage of APP. J Neurosci 2006; 26: 13428–13426
   PubMed Web of Science ®Google Scholar
• Marambaud P, Robakis N K. Genetic and molecular aspects of Alzheimer's disease shed light on new mechanisms of transcriptional regulation. Genes Brain Behav 2005; 4: 134–146
   PubMed Web of Science ®Google Scholar
• Nishimoto I, Okamoto T, Matsuura Y, Takahashi S, Okamoto T, Murayama Y, Ogata E. Alzheimer amyloid protein precursor complexes with brain GTP-binding protein G(o). Nature 1993; 362: 75–79
   PubMed Web of Science ®Google Scholar
• Russo C, Venezia V, Repetto E, Nizzari M, Violani E, Carlo P, Schettini G. The amyloid precursor protein and its network of interacting proteins: physiological and pathological implications. Brain Res Rev 2005; 48: 257–264
   PubMed Web of Science ®Google Scholar